Special attention should be paid to patients with prolactinomas requiring chronic treatment with dopamine agonists, in whom over the course of the years the accomplishment of suppressed of strongly reduced PRL levels has been interpreted as protective against tumour recurrence, thus encouraging the long-term maintenance of dopamine agonist doses able to drive PRL levels below the normal range. Here, PRL is linked to neoplasm.